Find Clinical Trials

Inclusion Criteria: * Adult patients ≥18 with hypertension who have follow-up for ≥6 months at the study settings * Have access to mobile or fixed telephones * Will stay for the study follow-up period Exclusion Criteria: * Participants who have coexisting severe mental health illnesses * Severe hearing impairments * Pregnant will be excluded

Inclusion Criteria: * Women aged 18 years or older and under 43 years of age * Patients with an indication for hysterectomy for a non-malignant condition * Patients who have provided explicit oral consent to participate * Patients covered by the French social security system * Patients able to read and understand French and capable of reading a French book within a timeframe compatible with the study schedule Exclusion Criteria: * Women with suspected uterine cancer or high-grade dysplasia * Women participating or having participated to an interventional clinical trial within the 30 days prior to inclusion * Pregnant, breastfeeding, or parturient women * Protected patient: adults under guardianship or other legal protection; persons deprived of liberty by judicial or administrative order; persons hospitalized without consent * Patients with insufficient proficiency in the French language

Inclusion Criteria: 1. Aged 12-18 years at the time of screening. 2. Current Major Depressive Disorder (MDD) documented in the electronic medical record by a licensed clinician; diagnosis verified using the Mental Health History - Parent Form. 3. Lives with a parent/legal guardian at least 50% of the time, confirmed on the Demographics Form. 4. Able and willing to provide assent, with a parent/legal guardian able and willing to provide informed consent. 5. Willingness to comply with all study procedures, including wearing a Fitbit Charge 5 for 7 nights, syncing the device through a compatible smartphone, and completing all required assessments (DERS-36, PHQ-9, anthropometrics, Youth Activity Profile, caffeine logs, PACHIQ-R). 6. Primary caregiver willing to participate, including completion of the PACHIQ-R (Caregiver). 7. If taking antidepressant medication, must be on a stable dose for at least 4 weeks before screening, verified on the Self-Administered Comorbidity Questionnaire. 8. English-speaking adolescent and caregiver, as all measures used in the study are validated in English. 9. Available for two in-person study visits within the study period. Exclusion Criteria 1. Medical conditions affecting autonomic function or HRV (arrhythmia, congenital heart disease, cardiomyopathy, Type 1 or Type 2 diabetes, thyroid disorders, or moderate-to-severe sleep apnea), as reported on the Self-Administered Comorbidity Questionnaire. 2. Use of medications known to affect heart rate or HRV, including beta-blockers, calcium channel blockers, antiarrhythmics, tricyclic antidepressants, stimulants, or antipsychotics, as documented on the NIMH Concomitant Medication Log. 3. Active substance use, including nicotine/tobacco, alcohol, marijuana, recreational drugs, or energy drinks, as assessed by the Drug Use Screening Inventory. 4. Habitual high caffeine intake (\>200 mg/day, equivalent to \>4 cups of coffee or \>2 cans of caffeinated soda per day), as assessed by a caffeine screening question during eligibility screening. 5. Psychotic disorders or active psychotic symptoms, as reported on the Mental Health History Questionnaire (Parent) and the Self-Administered Comorbidity Questionnaire. 6. Acute suicidal ideation requiring immediate intervention, defined as endorsement of agree and strongly agree on items 14-16 of the Concise Health Risk Tracking Self-Report (CHRT-SR), indicating active suicide risk. 7. Severe cognitive or intellectual impairment interfering with study participation, determined during eligibility screening based on parent report on the Mental Health History Questionnaire and observed inability to complete screening or consent procedures. 8. Current eating disorder diagnosis (anorexia nervosa, bulimia nervosa, or binge eating disorder), as reported on the Mental Health History Questionnaire. 9. Concurrent participation in another study involving wearable devices or daily monitoring, as reported on the Eligibility Screening Form. 10. Skin conditions or sensitivities prevent continuous wear of a wrist-worn device reported on the Eligibility Screening Form.

Inclusion Criteria (all): * age 50-80 years Inclusion Criteria (diabetes only): * Diagnosis of either type 1 diabetes or type 2 diabetes * Diabetes duration of ≥10 years for individuals with type 1 diabetes and ≥5 years for individuals with type 2 diabetes Exclusion Criteria: * HbA1c \>100 mmol/mol * Other type of diabetes * Weight \>140 Kg * Treatment with drugs that cannot be paused for 12 hours * Diagnosis of dementia * Active and recent (1year) malignant disease * History of major stroke * Major depression and/or treatment with antipsychotics * History of traumatic brain injury * Other medical condition or disorder (e.g., epilepsy, recent concussion) that in the opinion of the investigator precludes compliance with the protocol, evaluation of the results or represent an unacceptable risk for the participant's safety. * Inability to perform neuropsychological tests (e.g., severe vision and hearing impairment that cannot be improved with aids such as glasses and hearing aids, or language barrier.) * Severe claustrophobia * Foreign bodies of metal in the body which prohibits brain MRI scans (e.g. pacemaker or screws/plates from surgery in the head or neck region) * Participants who do not wish to be informed about accidental findings by MRI * eGFR measurement \<45 within 3 months of study visit

Inclusion Criteria: Age 14 to 60 years Both genders All patients with symptoms of uncontrolled asthma Exclusion Criteria: Patients with coexistent fungal sensitization (confirmed with peripheral eosinophil count and serum IgE) Patients with coexistent Allergic Bronchopulmonary Aspergillosis (ABPA) (confirmed with HRCT and serum IgE) Patients with coexistent COPD (confirmed on spirometry) Patients with Hypersensitivity Pneumonitis Patients with coexistent Interstitial Lung Disease (ILD) (confirmed on spirometry) Patients with coexistent cardiac asthma secondary to heart failure (diagnosed on echocardiography)

Inclusion Criteria: 1. Premature infants within 2 weeks of birth with a gestational age of 28 weeks or less or birth weight of less than 1,250g who require continuous invasive mechanical ventilation 2. When diagnosed with early pulmonary arterial hypertension satisfying condition ① or ② up to 14 days after birth: * When on or more of the following abnormal findings are present on echocardiography performed between 4 and 14 days after birth (findings at 1-3 days after birth correspond to early neonatal transition): 1. Sytemic or suprasystemic pulmonary artery pressure \>40mmHg(based on peak Doppler velocity of tricuspid regurgitation) 2. Right-to-left or bidirectional shunt through patent ductus arteriosus, foramen ovale, or atrial septal defect 3. Flattened interventricular septum or D-shaped left ventricle at end systole ② When receiving nitric oxide(NO) inhalation therapy for persistent pulmonary hypertension of the newborn(PPHN) within 3 days after birth Exclusion Criteria: 1. Those witth cyanotic congenital heart defects or acyanotic congenital heart defects causing heart failure, excluding patent ductus arteriosus in premature infatns 2. Those with severe pulmonary malformations such as congenital diaphragmatic hernia or congenital cystic lung disease 3. Those who underwent surgery within 72 hours before or after administration of the investigational cell product, or those for whom surgery is anticipated 4. Those who received surfactant within 24 hours prior to administration of the investigattional cell product 5. Those with chromosomal abnormalities accompanied by severe malformations(such as Edwards syndrome, Patau syndrome, Down syndrome, etc.) and severe congenital malformations(such as hydrocephalus, encephalocele, etc.) 6. Those with severe congenital infectious diseases(such as herpes, toxoplasmosis, rubella, syphilis, AIDS, etc.) 7. Those with severe sepsis or shock due to active infection not adequately treated with antibiotics 8. Those who have a history of participation in other advanced regenerative medicine clinical studies or clinical trials 9. Others deemed inappropriate by tthe investigator to participate in this advanced regenerative medicine clinical study

Inclusion Criteria: Older than 18 years old cT1-2 cN0 Negative preoperative assessment of the axilla Breast surgery as first treatment No axillary surgery Multifocal/ multicentric breast cancer Candidates to receive breast conserving surgery Written informed consent must be signed and dated by the patient and the investigator prior to inclusion. Patients must be accessible for follow-up. Exclusion Criteria Synchronous distant metastases Any axillary surgery Neoadjuvant treatment Previous malignancy Bilateral breast cancer Previous primary systemic therapy Pregnancy or breastfeeding Pre-operative diagnosis (cytology or histology) of axillary lymph node metastases Pre-operative radiological evidence of multiple involved or suspicious nodes Patients with psychiatric, addictive, or any disorder, which compromises their ability to give informed consent for participation in this study.

Participants are eligible to be included in the study only if they meet all of the following criteria: 1. Have signed the informed consent form (ICF) and are able to comply with the follow-up visits and related procedures required in the protocol. 2. Male or female participants: ≥18 years of age 3. Pathologically confirmed breast cancer: 1. Unresectable, locally advanced or metastatic breast cancer, i.e. participants who cannot be treated with curative intent and confirmed HER2-positive (HER2 IHC 3+ or HER2 ISH+) on specimens taken after confirmed locally advanced or metastatic disease by central testing. 2. Documented history of hormone receptor (HR)-positive (defined as estrogen receptor \[ER\] and/or progesterone receptor \[PgR\] positive \[ER or PgR ≥1%\]) or HR-negative after local testing in the metastatic setting according to ASCO/CAP guidelines. If a participant has more than one ER/PgR result after metastatic disease, the most recent result will be used. 4. No prior chemotherapy or HER2-targeted therapy for unresectable, locally advanced or metastatic breast cancer (first-line endocrine therapy is allowed for patients with metastatic breast cancer). Participants who have received chemotherapy or HER2-directed therapy in the neoadjuvant or adjuvant therapies and have a DFI of \>6 months from completion of systemic chemotherapy or HER2-targeted therapy to advanced or metastatic diagnosis are eligible. 5. Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1. 6. Evidence of radiographic or objective disease progression on or after the last systemic therapy prior to starting study treatment. 7. Have a life expectancy of ≥12 weeks at screening. 8. At least 1 measurable lesion as defined per RECIST v1.1 that has not been previously irradiated. Must be ≥ 10 mm in long axis (except for lymph nodes, which must be ≥ 15 mm in short axis) when accurately measured at baseline by CT or MRI (preferably with intravenous contrast) and the lesion is suitable for repeated accurate measurement. 9. Left ventricular ejection fraction (LVEF) ≥ 50% within 28 days prior to randomization. 10. Adequate organ and bone marrow function. Laboratory test values within 7 days prior to the first dose of the investigational product meet the following requirements in (if the laboratory tests during the screening period do not meet the following requirements, only one retest is allowed during the screening period): 1. Hemoglobin (HGB) ≥ 90 g/L (transfusion of red blood cells or erythropoietin are not allowed within 1 week prior to the screening assessment, and participants requiring ongoing transfusion or growth factor support to maintain hemoglobin ≥ 90 g/L are not eligible). 2. Absolute neutrophil count (ANC) ≥ 1.5 × 109 /L or within the normal range (G-CSF is not allowed within 1 week prior to the screening assessment). 3. Platelet (PLT) ≥ 90 × 109 /L (transfusion with platelets or thrombopoietin is not allowed within 1 week prior to screening assessment, participants requiring thrombopoietic growth factors to maintain adequate platelet count are not eligible). 4. Total bilirubin (TBIL) ≤ 1.5 × upper limit of normal (ULN) in the absence of liver metastasis; TBIL \< 3 × ULN in the presence of Gilbert syndrome (unconjugated hyperbilirubinemia) or liver metastasis. 5. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3×ULN (\<5×ULN for participants with liver metastases). 6. Serum albumin ≥ 25 g/L. 7. Serum creatinine ≤ 1.5 × ULN, or creatinine clearance ≥ 60 mL/min ( calculated using the Cockcroft-Gault formula ); if urinalysis indicates that the urine protein is \< 2+, participants with urine protein ≥ 2+ from urinalysis at baseline should undergo a 24-hour urine collection and have a 24-hour urine protein quantitation \< 1 g (if both methods are used, a 24-hour urine protein quantitation will be used to determine participant eligibility). Cockcroft/Gault formula: Female: CrCl = (140 - Age) × Weight (kg) × 0.85 72 × serum creatinine (mg/dL) Male: CrCl = (140 - years) × weight (kg) × 1.00 72 × serum creatinine (mg/dL) 8. International normalized ratio (INR) ≤ 1.5 × ULN, and prothrombin time (PT) or activated partial thromboplastin time (APTT) ≤ 1.5 × ULN. 11. Participants with evidence of postmenopausal status or negative serum pregnancy test (Sexually active, WOCBP with a non-sterilized male partner) must have a negative serum pregnancy test at the screening visit. WOCBP are women who are not surgically sterile (i.e., have undergone bilateral salpingectomy, bilateral oophorectomy, or total hysterectomy) or are not postmenopausal. 12. Female participants of childbearing potential or male participants with partners of childbearing potential must take effective contraceptive measures during the entire course of the trial and 6 months after the treatment Participants should not be included in the study if they meet any of the following criteria: 1. Prior treatment with antibody-drug conjugates containing camptothecin or its derivatives (topoisomerase I inhibitors). 2. Uncontrolled or significant cardiovascular and cerebrovascular diseases, including any of the following: 1. History of myocardial infarction or symptomatic congestive heart failure (New York Heart Association \[NYHA\] class II to IV) or uncontrolled myocarditis within 6 months before randomization. Participants with troponin levels above the ULN at screening (as specified by the manufacturer) and without any myocardial infarction-related symptoms should have a cardiology consultation before randomization to rule out myocardial infarction. 2. Uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg) despite of standard treatment. 3. History of any arterial thromboembolic events within 6 months prior to randomization, including myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack. 4. History of deep vein thrombosis, pulmonary embolism, or any other serious thromboembolic events within 3 months prior to randomization (thrombosis or catheter-derived thrombosis of caused by implanted venous ports, or superficial vein thrombosis, intermuscular vein thrombosis are not considered serious thromboembolisms). 5. History of arrhythmia (polymorphic premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia, ventricular fibrillation, torsades de pointes) that is symptomatic or requires treatment (CTCAE 5.0 Grade 3), atrial fibrillation that is symptomatic or uncontrolled despite treatment, or asymptomatic sustained ventricular tachycardia. Participants whose atrial fibrillation is controlled by medication or whose arrhythmia is controlled by a pacemaker will be allowed to be enrolled in the study. 6. Fridericia-corrected QT interval (QTcF) \>480 msec. If QTcF is \> 480 ms in 1 ECG during the screening period, 3 consecutive ECGs should be performed and the mean QTcF should be calculated. If QTcF is still \> 480 ms, the participant will not be enrolled. 7. History of QT prolongation associated with other drugs that require discontinuation, or any current concomitant medication known to prolong QT interval leading to Torsade de Pointes. 8. Congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death in first-degree relatives under 40 years old. 3. Non-infectious pneumonitis that requires corticosteroid treatment, or other clinically significant lung diseases such as a history of interstitial lung disease (ILD)/non-infectious pneumonitis, current ILD/non-infectious pneumonitis, or uncontrolled lung diseases (e.g., pulmonary fibrosis, severe radiation pneumonitis, and acute lung injury) or suspected ILD/non-infectious pneumonitis cannot be ruled out by imaging at screening. 4. Have a lung-specific intercurrent clinically significant illness including, but not limited to, any u

Inclusion Criteria: 1. Male or female participants aged 18 years or older at the time of signing the ICF. 2. Diagnosis of CRSwNP established for at least 52 weeks prior to tezepelumab initiation. 3. Availability of participants' medical records for at least 52 weeks prior to tezepelumab initiation, including history of sCS use / nasal polyps surgery (or information about contraindications / intolerance to). 4. Prescribed and initiated treatment with tezepelumab according to SmPC and local market reimbursement criteria. A period between treatment initiation and enrolment should be no more than 4 weeks. 5. The severity of CRSwNP consistent with need for surgery as defined by total NPS ≥ 5 (at least 2 for each nostril) at the enrollment. 6. Nasal Blockage score as part of SNOT-22 (NBS-SNOT-22) ≥ 3 at the enrollment. 7. SNOT-22 total score ≥ 30 at enrollment or up to 12 weeks before enrollment. 8. Currently receive care from specialist physicians (e.g., otolaryngologist) at the Investigator's or sub-Investigator's site. 9. Provision of signed and dated written informed consent. 10. Participants are able to read, understand and complete the questionnaires required by the protocol. Exclusion Criteria: 1. Any contraindication to tezepelumab as per the approved product SmPC in Russia or in the opinion of the Investigator. 2. Administration of concurrent biologic drug for CRSwNP / asthma since the index date, except for stable allergen immunotherapy (defined as a stable dose and regimen at the time of enrolment). Enrolment of patients who were switched from other biologic(s) to tezepelumab is allowed, and an acceptable timeframe since the last prior biologic drug is ≥ 60 days. The number of participants with prior biologic treatment (switching to tezepelumab) should be targeted at 20% or less. 3. Participation in an observational study that might, in the Investigator's opinion, influence the assessment for the current study, or participation in an interventional clinical trial in the last 3 months. 4. Pregnancy or lactation period.

Inclusion Criteria: * parents or main caregivers of children in the Autism Spectrum, * able to read and write in English. * 18 years or older Exclusion Criteria: * Paid caregivers * Unable to speak, read and write in English * Unable to follow instructions in English

Inclusion Criteria: 1. Male or female aged \>18 years at the time of consent 2. Breast cancer with progressive brain metastases supra and/or infratentorial. Patients can proceed with SRS as long as at least 1 lesion which is 2 cm or less in a noncritical area in the brain is spared as per the discretion of treating neurosurgeon/radiation oncologist. 3. At least one non irradiated, untreated progressive brain metastases site 4. Serum HCMV DNA by real time PCR \> 250 copies/ml or positive CMV Ig G or Ig M. 5. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form and in this protocol. If the patient is unable to consent for any reason a legally authorized guardian may provide consent on their behalf. Written informed consent and any locally required authorization (e.g., Health Insurance Portability and Accountability Act) will be obtained from the patient prior to performing any protocol-related procedures, including screening evaluations. 6. Metastatic breast cancer who has systemically no evidence of disease, complete remission, partial remission, stable or progressive disease 7. Eastern Cooperative Oncology Group (ECOG) performance score of 0-2 8. Adequate hematology without ongoing transfusion support (hemoglobin \> 9 g/dl, absolute neutrophil count (ANC) \> 1500 per mm3 , platelets \> 100,000 per mm3) 9. Adequate renal and hepatic function (creatinine clearance \[CrCL\] \> 60 mL/min, bilirubin x:≤1.5 upper limit of normal (ULN), aspartate aminotransferase \[AST\] and alanine aminotransferase \[ALT\] ≤ 2.5 x ULN and serum albumin ≥ 3 g/dl. 10. Other CMV treatment if clinically indicated per physician's choice 11. Evidence of postmenopausal status or negative serum pregnancy test for premenopausal female patients. Negative serum β-human chorionic gonadotropin pregnancy test within 7 days prior to the first dose of study treatment for premenopausal patients. Women will be considered postmenopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply: 12. Women \<50 years of age would be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the postmenopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy). 13. Women ≥50 years of age would be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses \>1 year ago, had chemotherapy-induced menopause with last menses \>1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy, or hysterectomy). 14. Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow-up. Exclusion Criteria: 1. Single resectable intracranial lesion 2. Last intracranial progression free survival \> 12 months 3. All progressive brain metastases have been radiated 4. Brain metastases needing immediate local intervention such as mass effect, herniation, active neurological symptoms, increased intracranial pressure, those near vital structures like the motor cortex, proximity to the optic nerve/chiasm or brain stem etc (can still be included if there are any other non-radiated progressive brain metastases) Multidisciplinary discussion with neurosurgery and radiation oncology will be needed to determine which patients may be safely enrolled on the trial. 5. Active pregnancy or breast feeding 6. Women of childbearing potential or fertile men unwilling to use effective contraception (Section 6.2, Table 6) during study and up to three months after treatment discontinuation. 7. Known psychiatric disorder that causes poor cooperation with the trial requirements. 8. Participants with previous other malignancies must have had at least a 3-year disease free interval, except those with non-melanoma skin cancer or carcinoma in situ of cervix 9. Participation in another clinical study with an investigational product within 28 days prior to the first dose of study treatment. 10. Concurrent enrollment in another clinical study unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study. 11. Unresolved or unstable adverse events (AEs) from prior administration of another investigational drug, per investigators' discretion. 12. Major surgical procedure (as defined by the investigator) within 28 days prior to the first dose of study treatment. 13. Non-English-speaking subjects will not be enrolled in this study since the neurocognitive tests including DKEFS, RAVLT and TMT are not validated to be scored in other languages.

Inclusion criteria - PAH patients: * Confirmed diagnosis of Pulmonary Arterial Hypertension * Age ≥ 18 years; * Ability to understand instructions and give informed consent; * Absence of neurological and psychiatric comorbidities; * Stable clinical condition, according to the treating physician's judgement; * Willingness to participate in the study for the entire duration of the tests. Inclusion criteria - Healthy controls: * Matching for age (± 3 years), gender, manual laterality and level of education: * No current or past organic and/or psychiatric disorders. Exclusion criteria for both groups: * Presence of medical, neurological or psychiatric comorbidities that could interfere with cognitive performance; * Use of drugs known to affect cognitive function; Presence of sensory and/or motor deficits that could compromise test performance; Insufficient understanding of spoken and/or written Italian; Inability to give free and/or informed consent.

Inclusion Criteria: * Age \>18 -Female * Diagnosis of non-metastatic breast cancer * Completion of primary treatment for breast cancer * No recurrence or metastasis; or no other cancer other than basal or squamous cell * Willingness to provide a private email address for all study activities * Ability to read and understand English Exclusion Criteria: * Inability to comply with one or more of the inclusion criteria

Inclusion Criteria: 1. Written informed consent. 2. Age 18-80 years. 3. Ability to read and understand German. 4. For patient cohorts: suspected or confirmed diagnosis of AD/MCI/depressive disorder with cognitive impairment according to clinical assessment and routine documentation. Exclusion Criteria: 1. Acute suicidality (e.g. BDI suicidality item \> 1). 2. Change of psychotropic medication within the last 4 weeks. 3. Lifetime psychotic disorder (ICD-10 F20-29). 4. Lack of capacity to consent. 5. Lifetime bipolar disorder (ICD-10 F31). 6. Acute substance abuse or harmful use of alcohol or other psychoactive substances. 7. Parkinson's syndrome (ICD-10 G20). 8. Multiple sclerosis (ICD-10 G35). 9. Stroke within the last 12 months.

Inclusion Criteria: Patients who meet all of the following criteria are eligible for inclusion in this study: * Male or female, age ≥18 years. * ECOG performance status ≤2, with an estimated life expectancy of \>3 months. * Histologically confirmed unresectable or metastatic breast cancer that is:HER2 IHC 1+ triple-negative breast cancer, or HR-positive/HER2-ultralow or HER2 IHC 1+ breast cancer. * Planned to receive monotherapy with Sacituzumab Govitecan and Trastuzumab Deruxtecan. * For triple-negative breast cancer: prior systemic therapy lines ≥1. * For HR-positive/HER2-negative metastatic breast cancer: prior endocrine therapy is required. Prior chemotherapy, immunotherapy, or targeted therapy is allowed; 0-2 lines of chemotherapy in the advanced/metastatic setting are permitted. * Prior treatment-related adverse events have recovered to ≤Grade 1 per NCI CTCAE v5.0 (except for alopecia, non-clinically significant or asymptomatic laboratory abnormalities). * Presence of at least one measurable or evaluable lesion. * Willingness to provide archival or fresh tumor tissue samples for multi-omics analysis, including: * Baseline prior to ADC1 treatment, * After 2 cycles of ADC1 therapy, * At progression on ADC1 therapy or baseline prior to ADC2 therapy, * At progression on ADC2 therapy. * FFPE tissue blocks are preferred over unstained slides. Patients must consent to tumor biopsy; if tissue is unavailable, biopsy is not feasible, or the patient declines biopsy, eligibility may be discussed and approved by the investigator. * No severe cardiac dysfunction, with left ventricular ejection fraction (LVEF) ≥50% within 28 days before treatment. * Adequate organ function within 7 days prior to treatment initiation: * Bone marrow: absolute neutrophil count (ANC) ≥1.5 × 10⁹/L; platelet count ≥100 × 10⁹/L; hemoglobin ≥90 g/L (no transfusion or blood component use within 14 days before first dose; no growth factor support within 7 days before first dose). * Liver: total bilirubin ≤1.5 × ULN (or \<3 × ULN if Gilbert's syndrome or documented liver metastases present); ALT and AST ≤2.5 × ULN (≤5 × ULN if liver metastases present). * Renal: serum creatinine ≤1.5 × ULN OR creatinine clearance ≥50 mL/min (calculated by Cockcroft-Gault formula). * Coagulation: INR ≤1.5 × ULN and aPTT ≤1.5 × ULN (unless therapeutically anticoagulated). * Voluntarily signed informed consent form and willingness to comply with the study protocol. * Willingness to provide complete clinical medical record data. Exclusion Criteria: Patients meeting any of the following criteria will be excluded from the study: * Contraindication or known hypersensitivity to sacituzumab govitecan, trastuzumab deruxtecan, or any of their components (including topoisomerase I inhibitors). * Prior treatment with sacituzumab govitecan, trastuzumab deruxtecan, or any other drug targeting the same molecular pathway. * History of another primary malignancy, except for: * Malignancy treated with curative intent with no evidence of active disease for ≥2 years prior to study intervention and with low risk of recurrence, or * Adequately treated carcinoma in situ of the cervix, stage I endometrioid carcinoma of the uterus, or non-melanoma skin cancer (e.g., basal cell carcinoma or squamous cell carcinoma). * Active infection or uncontrolled systemic disease, including but not limited to: * Active HIV, HBV, or HCV infection, * Active autoimmune disease, * Symptomatic pleural effusion, ascites, or pericardial effusion requiring drainage, * Severe or uncontrolled cardiac disease requiring treatment, * Poorly controlled diabetes or hypertension despite medical therapy. * Participation in another investigational drug trial within 4 weeks prior to the first study treatment (observational studies are permitted) or major surgery within 4 weeks prior to the first study treatment. * Prior anticancer therapy within specified timeframes: * Chemotherapy, radiotherapy, targeted therapy, or immunotherapy within 4 weeks before the first study treatment, * Anticancer endocrine therapy or traditional Chinese medicine with antitumor intent within 2 weeks before the first study treatment. * History of or current interstitial lung disease, severe chronic obstructive pulmonary disease, severe pulmonary insufficiency, symptomatic bronchospasm, or other clinically significant pulmonary disorders. * Pregnant or breastfeeding women, or women of childbearing potential with a positive pregnancy test at baseline; patients (male or female) who are unwilling to use effective contraception throughout the study period. * Known neurological or psychiatric disorders (e.g., epilepsy, dementia) or cognitive impairment that would compromise understanding of the study objectives, compliance, or ability to provide informed consent; or significant peripheral neuropathy. * Primary central nervous system (CNS) tumor or untreated/symptomatic CNS metastases. Patients with asymptomatic, stable CNS metastases not requiring steroids or specific CNS-directed therapy for at least 4 weeks prior to screening may be eligible. * Any other condition deemed unsuitable for participation by the investigator.

Inclusion Criteria: * Adults aged 18-65 years * Hospitalized in a psychiatric inpatient clinic * Diagnosed with schizophrenia, schizoaffective disorder, schizophreniform disorder, bipolar disorder with psychotic features, or major depressive disorder with psychotic features * Receiving psychotropic medication treatment * Clinically stable and able to participate in educational sessions * Able to communicate verbally and understand the content of the education * Provided written informed consent Exclusion Criteria: * Presence of severe cognitive impairment or intellectual disability * Acute medical or neurological conditions that may interfere with participation * Severe agitation or acute psychotic symptoms preventing participation * Hearing or communication impairments that limit participation in educational sessions * Participation in another psychosocial intervention study during the study period

Inclusion Criteria: 1. Voluntary consent to participate in this study and signing of the informed consent form. 2. The age of the signatory of the informed consent form should be ≥18 years old and ≤70 years old. 3. Advanced (locally recurrent inoperable or metastatic) TNBC confirmed by histology or cytology, defined as ER-negative, PR-negative, and HER2-negative. 4. PD-L1 IHC detection in tumor tissue with a CPS score ≥1. 5. Have received first-line standard immunotherapy combined with chemotherapy or immunotherapy combined with ADC and completed 6 cycles, with the last dose administered no more than 28 days before randomization. 6. The therapeutic efficacy was confirmed as CR, PR or SD after 6-cycle standard treatment according to the RECIST v1.1 criteria. 7. Plan to continue receiving immunotherapy. 8. An Eastern Cooperative Oncology Group performance-status score of 0 or 1. 9. The expected survival period exceeds 12 weeks. 10. Adequate organ function:. 11. No mental or intellectual abnormalities. 12. Willing and able to comply with the trial protocol during the trial period. 13. Female subjects of childbearing potential must agree to use highly effective contraceptive measures starting at least 7 days before the first dose and continuing until 24 weeks after the last dose. The serum pregnancy test result must be negative within 7 days prior to the first dose. Exclusion Criteria: 1. Untreated active brain metastases or meningeal metastases. 2. Concomitant other malignant tumors with progression within the recent 5 years or requiring active treatment (excluding adequately treated and controlled carcinoma in situ and non-melanoma skin cancer). 3. Concomitant severe non-malignant diseases that would affect the patient's compliance or put the patient at risk. 4. Concomitant active infection. 5. Receiving other anti-tumor therapies or participating in other interventional clinical trials. 6. Inflammatory breast cancer. 7. Dementia, intellectual disability, or any mental disorders that hinder the understanding of the informed consent form. 8. History of allergic reactions to any components of the study drugs or existing contraindications to their use. 9. Presence of any active autoimmune diseases or history of autoimmune diseases. 10. Presence of poorly controlled clinical cardiac symptoms or diseases, such as:1) Heart failure of NYHA class II or above;2) Unstable angina pectoris;3) Myocardial infarction occurring within 1 year;4) Clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention. 11. Presence of grade ≥3 toxicities related to prior treatments that restrict the continuation of maintenance therapy. 12. History of immunodeficiency, including HIV positivity, active HBV/HCV infection, other acquired or congenital immunodeficiency diseases, and history of organ or allogeneic stem cell transplantation. 13. Vaccination with live vaccines within 4 weeks prior to the administration of study drugs or planned vaccination during the study period. 14. Prior administration of irinotecan, topotecan, or any other topoisomerase I inhibitors (including investigational topoisomerase I inhibitors), or known history of allergies to the above-mentioned drugs. 15. Use of systemic glucocorticoids at a dose exceeding 10 mg/day of prednisone equivalent within 14 days prior to the administration of study drugs, or planned long-term use of the above dose during the study period (topical, inhaled, or short-term (≤7 days) pulse doses ≤10 mg/day of prednisone equivalent, or physiological dose replacement therapy are allowed for inclusion). 16. Need for use of any immunosuppressants within 14 days prior to the administration of study drugs or planned use during the study period. 17. Pregnant or lactating women, or women of childbearing potential who refuse to accept contraceptive measures. 18. Patients who are difficult or impossible to follow up. 19. Subjects judged by the investigator to have conditions that may affect compliance or other circumstances making them unsuitable for inclusion.

Inclusion Criteria: * Clinical diagnosis of MDD and eligible for aiTBS at MUSC * Already enrolled in aiTBS course at MUSC * English proficiency * Smartphone or willingness to use study-provided device Exclusion Criteria: * TMS contraindications (e.g., seizure history, implants, pregnancy) * Concurrent neuromodulation (ECT, VNS) * Psychotic disorder, bipolar disorder, active substance use disorder, high suicide risk * Unable/unwilling to engage in mindfulness or complete questionnaires

Inclusion Criteria: * Advanced Heart Failure (HF) with two HF-related hospitalizations within the last 12 months or * Advanced lung or non-colorectal gastrointestinal cancer (pancreatic, gastric, hepatobiliary, small bowel, esophageal) or tripe negative breast cancer with one hospitalization within the last 6 months * KPS \> or = 50% (ECOG 0, 1 or 2) * \> 2 outpatient MSHS visits in prior 12 months * Manhattan or Queens residence * Capacity to provide informed consent * English or Spanish fluency * \> or = 18 years of age Exclusion Criteria: * Diagnoses of both cancer and advanced HF * Lung cancer with a driver mutation (e.g., EGFR) that confers a favorable prognosis and does not follow typical trajectory * Patients with \> 1 visit to Outpatient Supportive Oncology/Cardiology visit * Patients with last visit to Outpatient Supportive Oncology/Cardiology \< 3 months ago * Previous receipt of a ventricular assist device or previous heart transplantation * Receiving hospice care prior to study enrollment or enrolled in another study of a palliative care patient/caregiver intervention * Living in a facility (subacute rehab, long-term care facility, hospice facility or residence) * Callahan 6-Item Cognitive Screening score ≤3

Sub-study 1 (Healthy individuals): * Age 23-50 years * BMI 20.0-26.9 kg/m² * HbA1c \< 42 mmol/mol * Able to provide informed consent Sub-study 2 - Participants with Type 2 Diabetes: * Age 23-60 years * Diagnosed with type 2 diabetes for ≥3 months * HbA1c \> 53 mmol/mol * Treatment with metformin only * Able to provide informed consent Sub-study 2 - Healthy control participants: * Age 23-64 years * HbA1c \< 42 mmol/mol * Able to provide informed consent Exclusion Criteria (applies to all participants unless otherwise specified): * Anaemia (haemoglobin below normal range) * ALT \> 2× upper normal limit or any known hepatobiliary or gastrointestinal disorder * Kidney disease (creatinine above normal range) * Previous gastric or intestinal resection (except appendectomy or cholecystectomy) or major abdominal surgery (including bariatric surgery) * For Sub-study 1: Type 1 or type 2 diabetes or HbA1c ≥ 42 mmol/mol * Use of glucose-lowering medications other than metformin (Sub-study 2 only) * Chronic obstructive pulmonary disease (Sub-study 2 only) * Regular tobacco smoking or use of nicotine-containing products * Claustrophobia * Pregnancy, breastfeeding, or intention to become pregnant during the study period * Initiation of special diets, major lifestyle changes, or weight loss \> 5% within 3 months prior to or during the study * Any medication or physical/psychological condition that may interfere with participation (per investigator judgement) * Inability to speak or read Danish